FDA tells Aveo no, again, for tivozanib as biotech tries to find yet another path forward

In a "Groundhog Day" scenario, the FDA has once more slapped down Aveo Oncology’s attempt to get its ill-fated cancer drug on the U.S. market.

The U.S. regulator outright refused to approve the drug, known as tivozanib, all the way back in 2013, but Aveo has kept plugging away, with no success.